Metabolize Secures $3.2 Million Seed Funding to Innovate Metabolic Health Solutions

Metabolize Raises $3.2 Million Seed Financing for Metabolic Health

In a significant development for the field of metabolic health, Metabolize, a consumer health company founded on groundbreaking research from Stanford Medicine, has announced the completion of its seed financing round, raising $3.2 million. This funding, led by Astanor, with participation from Maia Ventures, LongGame Venture, and SOSV, marks a pivotal step for the company as it looks to streamline the commercialization of its innovative solutions.

Dr. Morris Laster and Gideon Meir founded Metabolize in 2024, with a mission to harness the power of Precision Metabolite™ Technology, a sophisticated system cultivated from natural compounds identified through extensive research led by Dr. Jonathan Long at Stanford. The goal is to create a range of consumer products that align with the body's biology, making metabolic health accessible to all.

The announcement comes as the company gears up for the launch of its flagship product, NATLEAN, anticipated in January 2027. This new product is designed to support individuals transitioning off GLP-1 therapies, helping them manage appetite regulation and reduce food noise during their journey towards long-term weight management. It represents a key application of the Precision Metabolite™ Technology that underpins Metabolize's offering.

Dr. Laster, the CEO, emphasized the unmet needs in metabolic health. He stated, “GLP-1 therapies have revolutionized weight management, yet they do not address all challenges. As many individuals taper off or cannot use GLP-1s, there is a growing demand for scientifically backed solutions.” This sentiment underscores Metabolize’s commitment to researching and developing innovative products that cater to these gaps, ultimately striving to assist people in maintaining healthier lifestyles.

Metabolize's approach is not simply about creating dietary supplements but rather establishing a new class of metabolic health products driven by a scientific foundation. With clear mechanisms of action and consistent compositions derived from credible research, Metabolize aims to redefine consumer offerings in the metabolic health space.

The Importance of Scientific Backing

Each compound Metabolize is exploring has established biological functions that are well documented in scientific literature. By translating these findings into consumer-friendly products, the company sets itself apart in a crowded marketplace, prioritizing efficacy and safety.

Christina Ulardic, a partner at Astanor, expressed strong support for Metabolize’s vision, highlighting the vital need for scientific solutions in metabolic health. “Metabolic health is one of the most critical challenges faced by consumers today,” she said. “Metabolize stands out due to its focus on original research and a thoughtful approach to product development.”

By securing this funding, Metabolize is now poised to accelerate its research and manufacturing capabilities, enhancing its ability to bring science-backed metabolic health solutions to market effectively. The strategic backing from Astanor aligns with the firm's mission to invest in sustainable solutions throughout the agriculture and food sector, linking well with Metabolize’s health-oriented objectives.

Looking Ahead

As 2026 unfolds, Metabolize is gearing up for significant growth, underpinned by its exclusive rights to Stanford’s innovative research. With plans for additional products in development, the company seeks to broaden its portfolio and establish itself as a leader in metabolic health solutions.

For those concerned about their metabolic health or seeking to improve their wellness management, Metabolize’s innovative approach could soon provide reliable options backed by scientific research. Stay tuned as they approach the launch of NATLEAN and other products set to reshape how we understand and manage metabolic well-being.

For more information, visit their website at metabolize.life.